Serum free light chains in clinical laboratory diagnostics (original) (raw)

Comparison of the free and total light chain assays in serum and urine samples with immunofixation electrophoresis for detecting monoclonal proteins in patients with monoclonal gammopathy

Marta Morawska

Current Issues in Pharmacy and Medical Sciences, 2014

View PDFchevron_right

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

M. Boccadoro, Giampaolo Merlini

Leukemia, 2009

View PDFchevron_right

Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population

Nina Gulbrandsen

Clinical Chemistry, 2008

View PDFchevron_right

Diagnostic Performance of Quantitative and Free Light Chain Assays in Clinical Practice

Angela Dispenzieri

Clinical Chemistry, 2005

View PDFchevron_right

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

Tim Plant

BMC Nephrology, 2008

View PDFchevron_right

Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines

Aurore Perrot

Blood, 2016

View PDFchevron_right

The Value of Serum Immunoglobulin Free Light Chain Assessment in Patients with Monoclonal Gammopathies and Acute Renal Failure

Mustafa Cirit

Turkish Journal of Hematology, 2012

View PDFchevron_right

Understanding the Constraints and Optimization of Serum Immunofixation Electrophoresis and Serum Free Light Chains for Detecting Monoclonal Proteins: A Single-Center Experience

Malvika Shastri

Journal of Laboratory Physicians

View PDFchevron_right

Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: Correlation with 24-hr urinary light-chain excretion

Pierre Aucouturier

American Journal of Hematology, 2004

View PDFchevron_right

Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein

David Dingli

American journal of hematology, 2018

View PDFchevron_right

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Aurore Perrot

Blood, 2016

View PDFchevron_right

Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma

S. Murng

Clinical & Experimental Immunology, 2013

View PDFchevron_right

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test

Jennifer Pinney

BMC nephrology, 2017

View PDFchevron_right

A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay

OSMAN EVLİYAOĞLU

Hematology and Medical Oncology, 2019

View PDFchevron_right

Abnormal serum free light chain ratio does not always indicate monoclonal gammopathy

Bogdan Ochrem

Polskie Archiwum Medycyny Wewnętrznej, 2015

View PDFchevron_right

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach

Alberto Leivas

Diagnostics

View PDFchevron_right

IMMUNOGLOBULINS DETECTION AS BIOLOGICAL MARKERS OF MULTIPLE MYELOMA

Anil Batta

View PDFchevron_right

Serum Free Light Chain Ratio, Total / Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Luisa Giaccone

Clinical Chemistry, 2009

View PDFchevron_right

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests

James Child

British journal of haematology, 2017

View PDFchevron_right

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

Jennifer Pinney

BMC nephrology, 2018

View PDFchevron_right

Diagnostic sensitivity of a panel of tests to detect monoclonal protein in Korean multiple myeloma patients

Woochang Lee

Clinical Chemistry and Laboratory Medicine, 2013

View PDFchevron_right

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study

uros markovic

Cancers, 2021

View PDFchevron_right

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients

I. Radman, Klara Dubravcic

Croatian medical journal, 2015

View PDFchevron_right

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Tatiana Tzenou

British Journal of Haematology, 2007

View PDFchevron_right

Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool

Tim Plant

Clinical chemistry and laboratory medicine, 2016

View PDFchevron_right

The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma

Katerina Langova

Biomedical Papers, 2008

View PDFchevron_right

Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions

Mohamad Hussein

Clinical lymphoma, myeloma & leukemia, 2010

View PDFchevron_right